William Blair initiated coverage of Zevra Therapeutics with an Outperform rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZVRA:
- Zevra Therapeutics Releases New Investor Presentation
- Zevra Therapeutics Awaits FDA Decision on Arimoclomol
- Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
- Zevra Therapeutics says FDA extends review period for arimoclomol NDA
- Zevra Therapeutics to Participate at Upcoming Investor Conferences